NITROFURANTOIN SUSTAINED RELEASE 100mg. IP

A broad-spectrum bactericidal antibiotic and is effectively used to treat urinary tract infections. (Laishram Shakti, 2015) The first-line therapy for the treatment of uncomplicated lower urinary tract infections. (Squadrito & Daniel del Portal, Nitrofurantoin , 2021) A bactericidal agent against most common urinary tract pathogens, including Escherichia coli, Enterococci, Klebsiella, Staphylococcus saprophyticus, and Enterobacter. (Squadrito & Daniel del Portal, Nitrofurantoin , 2021) An effective therapeutic agent for the treatment of acute lower tract infections, chronic urinary tract infections, and for the suppression of catheter-associated bacteria. (B A Cunha, 1988) A well-tolerated drug that exerts good antimicrobial and clinical efficacy in the treatment of acute uncomplicated urinary tract infections in adults. (Arturo Mendoza-Valdes, 2010) Possesses good microbiological efficacy for chronic urinary tract infections caused by common uropathogens, with clinical cure rates varying between 79% and 92%. (Angela Huttner, 2015) A better alternative to fosfomycin for treating uncomplicated urinary tract infections in women. (Angela Huttner M. A.-R., 2018) The choice of agent for treating urinary tract infections caused by multi-drug resistant pathogens. (Laishram Shakti, 2015) Provides effective treatment of urinary tract infections caused by vancomycin-resistant enterococci. (George G. Zhanel, 2001) More effective than fosfomycin, trimethoprim for uncomplicated cystitis. (T. ten Doesschate, 2020)